Mind Medicine (MindMed) Inc.
MNMDMind Medicine (MindMed) Inc., doing business as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs.
Drugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
2
Next Catalyst
May 15, 2026
8dMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
MM120 (LSD D-Tartrate) Phase 3 Results Expected
Primary completion for MM120 (LSD D-Tartrate) trial (NCT06741228) in Generalized Anxiety Disorder
Source1 more catalyst beyond 14 days
Start a 48h free trial to see all upcoming catalysts
MM120 (LSD D-Tartrate)
Generalized Anxiety Disorder
MM-120
ADHD
MM402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA))
Autism Spectrum Disorder
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
MM120 (LSD D-Tartrate) | Phase 3 | Generalized Anxiety Disorder | - | - |
MM-120 | Phase 2 | ADHD | - | - |
MM402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA)) | Phase 2 | Autism Spectrum Disorder | - | - |